A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures.
about
Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewSafety of Levetiracetam in Paediatrics: A Systematic ReviewPerampanel for focal epilepsy: insights from early clinical experienceAntiepileptic Drug Treatment in Children with EpilepsyNeurobehavioral effects of levetiracetam in patients with traumatic brain injuryThe safety and tolerability of newer antiepileptic drugs in children and adolescents.Levetiracetam reduces abnormal network activations in temporal lobe epilepsy.Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of ageNewer antiepileptic drugs: evidence based use.Levetiracetam in neonatal seizures: a review.The importance of assessing behaviour and cognition in antiepileptic drug trials in children and adolescents.Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy.Neuropsychological implications of adjunctive levetiracetam in childhood epilepsyThe Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy.The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity.Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes.
P2860
Q26743786-492F7E3D-449D-42E0-BE9A-5B78B4193908Q26765160-E4276BD0-0581-45C2-A075-8C3C0639BCDAQ26778392-74970740-7325-4B3D-8B0F-0BF9D520FE24Q26781771-52ED0AC6-788C-47A5-BE6F-A9A6AB5F97DBQ26830325-E434943A-2512-47C0-A5A0-D6D99C525CDCQ30454834-796745D9-5C71-4532-91A1-0C8C505E02B6Q30597041-D88D025E-C553-4FD2-8C2B-67B1C3C10FD5Q38086370-DBAD3247-339B-4A1A-A9B6-92C884C292FFQ38222584-DAABB596-A01E-4240-8115-D8DF4F9B5824Q38474561-A76BEBBB-BF22-4D01-B03C-570C2C0C8939Q38779934-9366F5DA-DBEE-4321-84A3-FFF54A2EB7DBQ39206242-8B6959BD-0BFC-454A-87FD-C033BFF50AC2Q41964198-477581A1-C81C-4857-819C-C377DCF6E6EFQ47713007-B49ADCC4-0028-4C32-A9D1-62E18A73C3FAQ47716238-547EC21A-5EDF-42B3-841E-8104FF589DD6Q48099131-3AF97310-6F3A-479A-8450-A97993AD5D2E
P2860
A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A long-term open-label extensi ...... s with partial-onset seizures.
@en
A long-term open-label extensi ...... s with partial-onset seizures.
@nl
type
label
A long-term open-label extensi ...... s with partial-onset seizures.
@en
A long-term open-label extensi ...... s with partial-onset seizures.
@nl
prefLabel
A long-term open-label extensi ...... s with partial-onset seizures.
@en
A long-term open-label extensi ...... s with partial-onset seizures.
@nl
P2093
P2860
P356
P1476
A long-term open-label extensi ...... s with partial-onset seizures.
@en
P2093
Christine de la Loge
Daniel Legoff
Haichen Yang
Jimmy Schiemann-Delgado
John Jones
Mark Mintz
Tracy J Stalvey
P2860
P356
10.1177/0883073811417183
P577
2011-08-29T00:00:00Z